AstraZeneca
AZN
$68.94
Share price
0.00%
Change (1 day)
5.54%
Change (1 year)
Categories
AstraZeneca (AZN) - Cash on Hand
Cash on Hand as of June 2023 : $5.81 B
According to AstraZeneca's latest financial reports the company has $5.81 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
AstraZeneca - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $6.40 B | 0.11% |
| 2021-12-31 | $6.39 B | -19.94% |
| 2020-12-31 | $7.99 B | 28.53% |
| 2019-12-31 | $6.21 B | 9.47% |
| 2018-12-31 | $5.68 B | 24.73% |
| 2017-12-31 | $4.55 B | -22.84% |
| 2016-12-31 | $5.90 B | -13.88% |
| 2015-12-31 | $6.85 B | -4.22% |
| 2014-12-31 | $7.15 B | -28.54% |
| 2013-12-31 | $10.01 B | 17.47% |
| 2012-12-31 | $8.52 B | -27.88% |
| 2011-12-31 | $11.81 B | -5.82% |
| 2010-12-31 | $12.55 B | 9.84% |
| 2009-12-31 | $11.42 B | 160.21% |
| 2008-12-31 | $4.39 B | -27.35% |
| 2007-12-31 | $6.04 B | -22.11% |
| 2006-12-31 | $7.76 B | 17.52% |
| 2005-12-31 | $6.60 B | 25.41% |
| 2004-12-31 | $5.26 B | 33.26% |
| 2003-12-31 | $3.95 B | -15.76% |
| 2002-12-31 | $4.69 B | -14.17% |
| 2001-12-31 | $5.46 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $24.61 B | 323.49% | 🇺🇸 USA |
 Novartis NVS | $11.17 B | 92.26% | 🇨🇭 Switzerland |
 Pfizer PFE | $19.97 B | 243.63% | 🇺🇸 USA |
 Abbott Laboratories ABT | $9.53 B | 64.01% | 🇺🇸 USA |
 Eli Lilly LLY | $2.82 B | -51.32% | 🇺🇸 USA |
 Sanofi SNY | $8.68 B | 49.46% | 🇫🇷 France |
 Biogen BIIB | $6.07 B | 4.58% | 🇺🇸 USA |
 Merck MRK | $10.38 B | 78.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $8.37 B | 44.05% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $8.20 B | 41.17% | 🇬🇧 UK |